The U.S. Food and Drug Administration granted accelerated approval to Vitrakvi (larotrectinib, Loxo Oncology and Bayer) for the treatment of patients with solid tumors who have an NTRK gene fusion without a known resistance mutation.
How Diagnostic Testing Companies Work with Biotech
Katherine Stueland, Chief Commercial Officer at Invitae, discusses how diagnostic companies work with biotech companies. Katherine also discusses the role of genetic companies in assisting patients and physicians in diagnosing rare diseases.
Sickle Cell Trait Increases Risk for Some Health Conditions
In the United States, an estimated 2.5 to 3 million people have a gene variant associated sickle cell trait (SCT) and most never have related health complications. Researchers have now identified three health conditions for which people with SCT are at increased risk.
Dravet Syndrome Overview
Barry Ticho, MD, Chief Medical Officer at Stoke Therapeutics, provides an overview of Dravet syndrome, a severe form of epilepsy that is part of a group of diseases known as SCN1A-related seizure disorders.
Partnerships Between Genetic Testing Companies and Drug Developers
Katherine Stueland, Chief Commercial Officer at Invitae, discusses how genetic testing companies partner with drug developers, including her company’s work with Alnylam.
The Important Role of Diagnostic Companies in Rare Diseases
Katherine Stueland, Chief Commercial Officer at Invitae, discusses the roles of genetic companies in assisting patients and physicians in diagnosing rare diseases.
